These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27941526)

  • 21. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
    Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum neuron specific enolase level as a predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis.
    Lu K; Xu X; Cui S; Wang F; Zhang B; Zhao Y
    J Neurol Sci; 2015 Dec; 359(1-2):202-6. PubMed ID: 26671113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroke scale items associated with neurologic deterioration within 24 hours after recombinant tissue plasminogen activator therapy.
    Nanri Y; Yakushiji Y; Hara M; Eriguchi M; Okada R; Yukitake M; Hara H
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1117-24. PubMed ID: 23199533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?
    Shaltoni HM; Albright KC; Gonzales NR; Weir RU; Khaja AM; Sugg RM; Campbell MS; Cacayorin ED; Grotta JC; Noser EA
    Stroke; 2007 Jan; 38(1):80-4. PubMed ID: 17122433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.
    Takagi T; Kato T; Sakai H; Nishimura Y
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):69-74. PubMed ID: 23164483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
    Hacke W; Donnan G; Fieschi C; Kaste M; von Kummer R; Broderick JP; Brott T; Frankel M; Grotta JC; Haley EC; Kwiatkowski T; Levine SR; Lewandowski C; Lu M; Lyden P; Marler JR; Patel S; Tilley BC; Albers G; Bluhmki E; Wilhelm M; Hamilton S; ; ;
    Lancet; 2004 Mar; 363(9411):768-74. PubMed ID: 15016487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On- versus Off-Hour Patient Cohorts at a Primary Stroke Center: Onset-to-Treatment Duration and Clinical Outcomes after IV Thrombolysis.
    Asuzu D; Nystrӧm K; Amin H; Schindler J; Wira C; Greer D; Chi NF; Halliday J; Sheth KN
    J Stroke Cerebrovasc Dis; 2016 Feb; 25(2):447-51. PubMed ID: 26654664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapidly improving stroke symptoms: a pilot, prospective study.
    Balucani C; Bianchi R; Ramkishun C; Weedon J; Law S; Szarek M; Rojas-Soto D; Tariq S; Levine SR
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1211-6. PubMed ID: 25869774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis.
    Yong M; Diener HC; Kaste M; Mau J
    Cerebrovasc Dis; 2007; 24(4):349-54. PubMed ID: 17690547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [ASPECTS-DWI, arterial occlusion sites and subtype of acute ischemic stroke have a relation with outcome following intravenous rt-PA therapy].
    Idei M; Sasaki T; Tanabe T; Muraoka K; Terada K; Meguro T; Hirotsune N; Nishino S
    No Shinkei Geka; 2012 Jul; 40(7):585-91. PubMed ID: 22728535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI-based ultrafast protocol thrombolysis with rt-PA for acute ischemia stroke in 12-hour time window.
    Li YH; Li MH; Zhao JG; Wang W
    J Neuroimaging; 2011 Oct; 21(4):332-9. PubMed ID: 21121996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry.
    Aoki J; Kimura K; Koga M; Kario K; Nakagawara J; Furui E; Shiokawa Y; Hasegawa Y; Okuda S; Yamagami H; Okada Y; Shibazaki K; Sakamoto Y; Toyoda K
    J Neurol Sci; 2013 Apr; 327(1-2):6-11. PubMed ID: 23433814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
    IMS Study Investigators
    Stroke; 2004 Apr; 35(4):904-11. PubMed ID: 15017018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
    Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
    Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.